To assign ABA research authorship contribution data ownership intellectual property and publication duties, document each contributor's work, accountability, data access, institutional role, employment terms, agreements, intellectual-property permissions, conflicts, acknowledgments, publication control, and correction responsibility early. Revisit the record as contributions change. Authorship, data custody, copyright, confidentiality, and permission to publish answer different questions, so one label or contract should not silently decide them all.

Define Farah's governed activity and unit

A contribution agreement makes work and accountability visible before deadlines, hierarchy, or publication pressure distort credit and control. Teams using this guide need the exact activity, people, purpose, design, data, site, sponsor, funding, institutional scope, authority, current version, participant protections, and unresolved facts before work begins.

Build Farah's research contribution and publication agreement

Farah records project and protocol, investigators, client or community contributors, conceptualization, methods, implementation, data curation, software, analysis, visualization, writing, supervision, funding, administration, accountability, conflicts, employer and institution, data ownership and custody, access, intellectual-property terms, confidential material, acknowledgments, author order, corresponding role, publication approval, repository deposits, presentations, AI or contractor assistance, contributor changes, dispute route, correction, and retention. The agreement preserves participant communication authorship and approved reuse limits.

Protect participants and ordinary care in Farah's workflow

Farah's twelve multi-role research and program-evaluation projects must preserve client dignity, ordinary clinical access, voluntary choice, privacy, communication and AAC, authorized decision-making, safety response, equitable treatment, complaints, and freedom from retaliation. A research label, consent signature, payment, supervisor approval, or publication goal cannot expand a role or erase a required protection.

Work through Farah's fictional example

Farah reviews 12 projects. Nine have current signed contribution, data, conflict, and publication records. One omits a staff analyst, one assigns authorship solely by job title, and one lacks authority for a borrowed figure. The three remain open until the project record is corrected. Preserve every proposed, classified, reviewed, approved, exempted, enrolled, changed, reported, published, corrected, held, withdrawn, and closed state with its original version, owner, date, conditions, and validation.

Use Farah's denominator carefully

Agreement completeness is nine of 12, or 75%. The three open projects remain in the original cohort. Contributor count, author count, datasets, publications, presentations, and correction actions use separate denominators.

Assign Farah's decisions to authorized owners

Farah coordinates the agreement. Contributors attest to work and accountability. Institutions, employers, data owners, funders, journals, and intellectual-property owners exercise their actual rights. Qualified research and legal reviewers resolve scope; a senior title alone does not award authorship or data control.

Address Farah's main interpretation risk

Teams may postpone credit decisions until submission, when employment power and deadlines make disagreement harder to resolve. Early records also expose missing accountability and permissions.

Verify Farah's research control in practice

Farah traces a table, quotation, code output, and conclusion to its contributor, source, analysis version, permission, and accountable reviewer. A person unfamiliar with the hierarchy compares the record with the draft byline and acknowledgments.

Place Farah's project inside organizational accountability

Farah's research contribution and publication agreement uses the CASP Organizational Guidelines public overview only for high-level business, clinical-operations, and risk-management scope in autism service organizations. CASP sells the detailed guidelines. The workflow here is Finni's editorial governance model, not a CASP research protocol, regulatory determination, or institutional approval.

Apply the BACB research duties to Farah's covered roles

Farah's role review uses the current BACB Ethics Code, which applies to BCBA and BCaBA certificants and people who completed an application. Its research section addresses applicable review, participant welfare, informed consent, confidentiality, competence, conflicts, integrity, authorship, publication, and corrections. BACB has no separate organization or corporation jurisdiction, so institutional and legal controls remain necessary.

Anchor Farah's federal scope to the current HHS rule

Farah's federal analysis starts with the HHS 45 CFR 46 page, reviewed in February 2025, which identifies the 2018 Requirements and added subparts for specified populations. Applicability depends on funding, conduct, assurance, institution, activity, and other facts. The page is an authoritative starting point, while the current rule and responsible institution control the determination.

Use the OHRP decision charts as aids for Farah

Farah's reviewer may use the OHRP 2018 Requirements decision charts to organize research, human-subject, exemption, continuing-review, and consent-waiver questions. OHRP calls the charts generalizations and directs users to the full applicable text. They support intake and discussion; they do not authorize an investigator to self-approve a project.

Classify quality improvement carefully for Farah

Farah's project label follows the OHRP Quality Improvement Activities FAQs. OHRP explains that intent to publish is insufficient to decide whether QI is research and that some QI can be nonexempt human-subjects research. Purpose, design, activity, coverage, and an authorized determination matter more than the label chosen by the project team.

Separate HIPAA research permission for Farah

Farah's privacy review uses HHS research guidance under HIPAA, which explains that covered entities may use or disclose PHI for research with individual authorization or through limited rule-defined paths without authorization. Common Rule consent, IRB action, HIPAA authorization or waiver, data-owner approval, and contract terms remain separate decisions even when one document combines information.

Treat informed consent as a process for Farah

Farah's communication plan draws on the OHRP Informed Consent FAQs. OHRP flags that the FAQ predates the 2018 Requirements and 2024 conforming changes, while retaining general nonbinding guidance. Use the current regulation and review decision. The FAQ describes prospective, legally effective, voluntary information exchange with questions and a real choice to join, continue, or withdraw.

Apply child-research requirements precisely for Farah

Farah's child-participant route uses current 45 CFR 46 Subpart D, amended in October 2024. The IRB determines adequate provisions for parental or guardian permission and for child assent when the child is capable, subject to the rule's conditions and possible waivers. Clinical assent policies and research assent determinations should be recorded separately.

Distinguish adverse events and unanticipated problems for Farah

Farah's incident logic uses OHRP guidance on unanticipated problems and adverse events. The guidance explains that only a subset of adverse events are unanticipated problems and describes unexpectedness, relation or possible relation, and increased risk as the three-part analysis. Use the current protocol, institution, and rules for actual reporting decisions and deadlines.

Scope research-misconduct handling for Farah

Farah's integrity route recognizes the 2024 final rule revising 42 CFR Part 93. The rule became effective January 1, 2025, and its regulatory requirements apply beginning January 1, 2026, to covered Public Health Service research-misconduct matters. Allegations received before that applicability date generally follow the 2005 rule unless the institution and respondent elect the new rule in writing. The current rule addresses fabrication, falsification, and plagiarism and excludes honest error or differences of opinion. Other sponsors, institutions, journals, employers, and laws can use different processes; preserve allegations as allegations until the authorized process decides them.

Make Farah's participation process accessible

Farah's access plan uses DOJ effective-communication guidance for covered title II or title III entities. The appropriate aid or service depends on the interaction's nature, length, complexity, context, and the person's usual communication method. Apply the actual entity and rule, preserve AAC and authorship, and test consent, recruitment, questions, incident notices, and withdrawal routes in the formats participants use.

Choose Farah's next review trigger

Review after personnel, role, analysis, funding, institution, data, author order, journal, figure, presentation, conflict, contributor objection, correction, or withdrawal changes. Record the changed fact, affected people and records, immediate protection, governing source, decision owner, reporting or amendment route, deadlines, communication, and validation result.

Close Farah's record with accountable evidence

Review the research contribution and publication agreement with Farah, investigators, qualified clinicians, the institution or reviewing body, participant representatives as applicable, and the specialists named in the manifest. Confirm that service, QI, evaluation, research, review, consent, privacy, safety, data, employment, authorship, publication, and misconduct routes remain distinct; all conditions are traceable; access is tested; and unresolved work has an accountable endpoint. Keep this page draft and noindex until every required review is complete.

Related resources

Sources